Literature DB >> 27183620

Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.

Byram W Bridle1, Andrew Nguyen2, Omar Salem2, Liang Zhang2, Sandeep Koshy2, Derek Clouthier2, Lan Chen2, Jonathan Pol2, Stephanie L Swift2, Dawn M E Bowdish2, Brian D Lichty2, Jonathan L Bramson2, Yonghong Wan3.   

Abstract

Effector T cells (TEFF) are a barrier to booster vaccination because they can rapidly kill Ag-bearing APCs before memory T cells are engaged. We report in this study that i.v. delivery of rhabdoviral vectors leads to direct infection of follicular B cells in the spleen, where the earliest evidence of secondary T cell responses was observed. This allows booster immunizations to rapidly expand CD8(+) central memory T cells (TCM) during the acute phase of the primary response that is dominated by TEFF Interestingly, although the ablation of B cells before boosting with rhabdoviral vectors diminishes the expansion of memory T cells, B cells do not present Ags directly. Instead, depletion of CD11c(+) dendritic cells abrogates secondary T cell expansion, suggesting that virus-infected follicular B cells may function as an Ag source for local DCs to subsequently capture and present the Ag. Because TCM are located within B cell follicles in the spleen whereas TEFF cannot traffic through follicular regions, Ag production and presentation by follicular APCs represent a unique mechanism to secure engagement of TCM during an ongoing effector response. Our data offer insights into novel strategies for rapid expansion of CD8(+) T cells using prime-boost vaccines by targeting privileged sites for Ag presentation.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27183620     DOI: 10.4049/jimmunol.1600106

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 2.  Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.

Authors:  Nikolas Tim Martin; John Cameron Bell
Journal:  Mol Ther       Date:  2018-04-05       Impact factor: 11.454

3.  Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.

Authors:  Scott R Walsh; Donald Bastin; Lan Chen; Andrew Nguyen; Christopher J Storbeck; Charles Lefebvre; David Stojdl; Jonathan L Bramson; John C Bell; Yonghong Wan
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

4.  Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.

Authors:  Scott R Walsh; Boris Simovic; Lan Chen; Donald Bastin; Andrew Nguyen; Kyle Stephenson; Talveer S Mandur; Jonathan L Bramson; Brian D Lichty; Yonghong Wan
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

5.  Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Authors:  Matthew J Atherton; Kyle B Stephenson; Fanny Tzelepis; David Bakhshinyan; Jake K Nikota; Hwan Hee Son; Anna Jirovec; Charles Lefebvre; Anna Dvorkin-Gheva; Ali A Ashkar; Yonghong Wan; David F Stojdl; Eric C Belanger; Rodney H Breau; John C Bell; Fred Saad; Sheila K Singh; Jean-Simone Diallo; Brian D Lichty
Journal:  Oncoimmunology       Date:  2018-03-27       Impact factor: 8.110

Review 6.  Peptide vaccines in cancer-old concept revisited.

Authors:  Takumi Kumai; Hiroya Kobayashi; Yasuaki Harabuchi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2016-12-09       Impact factor: 7.486

7.  Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.

Authors:  D G Roy; K Geoffroy; M Marguerie; S T Khan; N T Martin; J Kmiecik; D Bobbala; A S Aitken; C T de Souza; K B Stephenson; B D Lichty; R C Auer; D F Stojdl; J C Bell; M-C Bourgeois-Daigneault
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

Review 8.  Oncolytic Viruses: Therapeutics With an Identity Crisis.

Authors:  Caroline J Breitbach; Brian D Lichty; John C Bell
Journal:  EBioMedicine       Date:  2016-07-02       Impact factor: 8.143

9.  Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats.

Authors:  Jeff Hummel; Dorothee Bienzle; Annette Morrison; Michelle Cieplak; Kyle Stephenson; Josepha DeLay; J Paul Woods; Brian D Lichty; Byram W Bridle
Journal:  Sci Rep       Date:  2017-11-16       Impact factor: 4.379

Review 10.  Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.

Authors:  Donald Bastin; Scott R Walsh; Meena Al Saigh; Yonghong Wan
Journal:  Biomedicines       Date:  2016-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.